Methylenetetrahydrofolate reductase (MTHFR) inhibitors constitute a diverse chemical class of compounds that interact with the MTHFR enzyme, which plays a crucial role in folate metabolism. The MTHFR enzyme is responsible for catalyzing the conversion of 5,10-methylenetetrahydrofolate (5,10-MTHF) to 5-methyltetrahydrofolate (5-MTHF), a critical step in the folate cycle. This conversion is essential for the synthesis of nucleotides, DNA methylation, and other crucial cellular processes. The chemical class of MTHFR inhibitors encompasses various molecules with distinct structures and mechanisms of action. Some inhibitors are competitive, while others may act allosterically to interfere with the catalytic activity of the MTHFR enzyme. Many compounds target the active site of the enzyme, disrupting its ability to bind the cofactor NAD(P)H or the substrate 5,10-MTHF.
One group of MTHFR inhibitors includes analogs of 5,10-MTHF, which possess structural similarities to the natural substrate. These analogs can competitively bind to the active site of the enzyme, stopping the binding of the endogenous substrate and reducing the conversion rate. Another class of inhibitors consists of compounds that interfere with the electron transfer process required for MTHFR activity. By disrupting electron transfer, these inhibitors disrupt the enzyme's redox function and lead to reduced catalytic efficiency. Researchers have also investigated allosteric MTHFR inhibitors that bind to distinct sites on the enzyme, not directly related to the active site. By binding at allosteric sites, these inhibitors can induce conformational changes that alter the enzyme's overall activity and reduce its effectiveness in converting 5,10-MTHF to 5-MTHF. The chemical class of MTHFR inhibitors plays a vital role in scientific research and contributes to a deeper understanding of the complex pathways involving folate metabolism. These inhibitors serve as valuable tools for investigating the physiological and biochemical functions of MTHFR in various biological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate inhibits dihydrofolate reductase, an enzyme involved in the conversion of dihydrofolate to tetrahydrofolate, an essential step in folate metabolism. | ||||||
Aminopterin | 54-62-6 | sc-202461 | 50 mg | $102.00 | 1 | |
Aminopterin is another folate antagonist and inhibitor of dihydrofolate reductase, similar to methotrexate. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $66.00 $158.00 $204.00 $707.00 $3334.00 | 4 | |
Trimethoprim is an antibiotic that inhibits bacterial dihydrofolate reductase, leading to the disruption of bacterial folate metabolism and subsequent cell death. | ||||||
Pyrimethamine | 58-14-0 | sc-208190 sc-208190A sc-208190B | 1 g 5 g 25 g | $78.00 $233.00 $809.00 | 5 | |
Pyrimethamine is an antiparasitic agent that also inhibits dihydrofolate reductase. | ||||||
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid | 137281-23-3 | sc-479733 | 250 mg | $330.00 | 1 | |
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid is an anticancer agent that inhibits multiple enzymes involved in folate metabolism, including thymidylate synthase and dihydrofolate reductase. | ||||||
Sulfamethoxazole | 723-46-6 | sc-208405 sc-208405A sc-208405B sc-208405C | 10 g 25 g 50 g 100 g | $36.00 $54.00 $68.00 $107.00 | 5 | |
Sulfamethoxazole is an antibiotic that inhibits the enzyme dihydropteroate synthase, which is involved in folate synthesis in bacteria. | ||||||